Browse FGF2

Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted. Nucleus. Note=Exported from cells by an endoplasmic reticulum (ER)/Golgi-independent mechanism. Unconventional secretion of FGF2 occurs by direct translocation across the plasma membrane. Binding of exogenous FGF2 to FGFR facilitates endocytosis followed by translocation of FGF2 across endosomal membrane into the cytosol. Nuclear import from the cytosol requires the classical nuclear import machinery, involving proteins KPNA1 and KPNB1, as well as CEP57.
Domain PF00167 Fibroblast growth factor
Function

Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:8663044). Also acts as an integrin ligand which is required for FGF2 signaling (PubMed:28302677). Binds to integrin ITGAV:ITGB3 (PubMed:28302677). Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration (PubMed:8663044, PubMed:28302677). Functions as a potent mitogen in vitro (PubMed:3732516, PubMed:3964259). Can induce angiogenesis (PubMed:23469107, PubMed:28302677).

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0001501 skeletal system development
GO:0001525 angiogenesis
GO:0001655 urogenital system development
GO:0001657 ureteric bud development
GO:0001658 branching involved in ureteric bud morphogenesis
GO:0001667 ameboidal-type cell migration
GO:0001708 cell fate specification
GO:0001763 morphogenesis of a branching structure
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0002040 sprouting angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0006022 aminoglycan metabolic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006066 alcohol metabolic process
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007265 Ras protein signal transduction
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0008654 phospholipid biosynthetic process
GO:0010453 regulation of cell fate commitment
GO:0010455 positive regulation of cell fate commitment
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010594 regulation of endothelial cell migration
GO:0010595 positive regulation of endothelial cell migration
GO:0010596 negative regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010761 fibroblast migration
GO:0010762 regulation of fibroblast migration
GO:0010764 negative regulation of fibroblast migration
GO:0010863 positive regulation of phospholipase C activity
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014706 striated muscle tissue development
GO:0014841 skeletal muscle satellite cell proliferation
GO:0014842 regulation of skeletal muscle satellite cell proliferation
GO:0014843 growth factor dependent regulation of skeletal muscle satellite cell proliferation
GO:0014855 striated muscle cell proliferation
GO:0014856 skeletal muscle cell proliferation
GO:0014857 regulation of skeletal muscle cell proliferation
GO:0016202 regulation of striated muscle tissue development
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019216 regulation of lipid metabolic process
GO:0019751 polyol metabolic process
GO:0019827 stem cell population maintenance
GO:0030198 extracellular matrix organization
GO:0030203 glycosaminoglycan metabolic process
GO:0030212 hyaluronan metabolic process
GO:0030214 hyaluronan catabolic process
GO:0030258 lipid modification
GO:0030335 positive regulation of cell migration
GO:0030336 negative regulation of cell migration
GO:0031334 positive regulation of protein complex assembly
GO:0032102 negative regulation of response to external stimulus
GO:0032103 positive regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032958 inositol phosphate biosynthetic process
GO:0033002 muscle cell proliferation
GO:0033674 positive regulation of kinase activity
GO:0035019 somatic stem cell population maintenance
GO:0035239 tube morphogenesis
GO:0035265 organ growth
GO:0035766 cell chemotaxis to fibroblast growth factor
GO:0035767 endothelial cell chemotaxis
GO:0035768 endothelial cell chemotaxis to fibroblast growth factor
GO:0036092 phosphatidylinositol-3-phosphate biosynthetic process
GO:0040013 negative regulation of locomotion
GO:0040017 positive regulation of locomotion
GO:0042659 regulation of cell fate specification
GO:0042660 positive regulation of cell fate specification
GO:0043062 extracellular structure organization
GO:0043254 regulation of protein complex assembly
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043536 positive regulation of blood vessel endothelial cell migration
GO:0043537 negative regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0043550 regulation of lipid kinase activity
GO:0043551 regulation of phosphatidylinositol 3-kinase activity
GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity
GO:0043647 inositol phosphate metabolic process
GO:0044089 positive regulation of cellular component biogenesis
GO:0044283 small molecule biosynthetic process
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0045017 glycerolipid biosynthetic process
GO:0045165 cell fate commitment
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045834 positive regulation of lipid metabolic process
GO:0045844 positive regulation of striated muscle tissue development
GO:0045860 positive regulation of protein kinase activity
GO:0045927 positive regulation of growth
GO:0046165 alcohol biosynthetic process
GO:0046173 polyol biosynthetic process
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046620 regulation of organ growth
GO:0046622 positive regulation of organ growth
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048514 blood vessel morphogenesis
GO:0048634 regulation of muscle organ development
GO:0048636 positive regulation of muscle organ development
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048738 cardiac muscle tissue development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051216 cartilage development
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051271 negative regulation of cellular component movement
GO:0051272 positive regulation of cellular component movement
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051302 regulation of cell division
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051781 positive regulation of cell division
GO:0055017 cardiac muscle tissue growth
GO:0055021 regulation of cardiac muscle tissue growth
GO:0055023 positive regulation of cardiac muscle tissue growth
GO:0055024 regulation of cardiac muscle tissue development
GO:0055025 positive regulation of cardiac muscle tissue development
GO:0055074 calcium ion homeostasis
GO:0060038 cardiac muscle cell proliferation
GO:0060043 regulation of cardiac muscle cell proliferation
GO:0060045 positive regulation of cardiac muscle cell proliferation
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0060326 cell chemotaxis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0060419 heart growth
GO:0060420 regulation of heart growth
GO:0060421 positive regulation of heart growth
GO:0060537 muscle tissue development
GO:0060562 epithelial tube morphogenesis
GO:0060591 chondroblast differentiation
GO:0060675 ureteric bud morphogenesis
GO:0060993 kidney morphogenesis
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0061138 morphogenesis of a branching epithelium
GO:0061326 renal tubule development
GO:0061333 renal tubule morphogenesis
GO:0061448 connective tissue development
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0071774 response to fibroblast growth factor
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072028 nephron morphogenesis
GO:0072073 kidney epithelium development
GO:0072078 nephron tubule morphogenesis
GO:0072080 nephron tubule development
GO:0072088 nephron epithelium morphogenesis
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072171 mesonephric tubule morphogenesis
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090218 positive regulation of lipid kinase activity
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0097553 calcium ion transmembrane import into cytosol
GO:0098727 maintenance of cell number
GO:1900274 regulation of phospholipase C activity
GO:1901136 carbohydrate derivative catabolic process
GO:1901342 regulation of vasculature development
GO:1901565 organonitrogen compound catabolic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1901861 regulation of muscle tissue development
GO:1901863 positive regulation of muscle tissue development
GO:1902656 calcium ion import into cytosol
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903510 mucopolysaccharide metabolic process
GO:1903670 regulation of sprouting angiogenesis
GO:1903672 positive regulation of sprouting angiogenesis
GO:1903725 regulation of phospholipid metabolic process
GO:1903727 positive regulation of phospholipid metabolic process
GO:1904018 positive regulation of vasculature development
GO:1904847 regulation of cell chemotaxis to fibroblast growth factor
GO:1904849 positive regulation of cell chemotaxis to fibroblast growth factor
GO:2000021 regulation of ion homeostasis
GO:2000146 negative regulation of cell motility
GO:2000147 positive regulation of cell motility
GO:2000544 regulation of endothelial cell chemotaxis to fibroblast growth factor
GO:2000546 positive regulation of endothelial cell chemotaxis to fibroblast growth factor
GO:2001026 regulation of endothelial cell chemotaxis
GO:2001028 positive regulation of endothelial cell chemotaxis
Molecular Function GO:0003713 transcription coactivator activity
GO:0004713 protein tyrosine kinase activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005104 fibroblast growth factor receptor binding
GO:0005125 cytokine activity
GO:0005539 glycosaminoglycan binding
GO:0008083 growth factor activity
GO:0008201 heparin binding
GO:0016303 1-phosphatidylinositol-3-kinase activity
GO:0030374 ligand-dependent nuclear receptor transcription coactivator activity
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0042056 chemoattractant activity
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0052742 phosphatidylinositol kinase activity
GO:0052813 phosphatidylinositol bisphosphate kinase activity
GO:0070851 growth factor receptor binding
GO:1901681 sulfur compound binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-2033519: Activated point mutants of FGFR2
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-5654687: Downstream signaling of activated FGFR1
R-HSA-5654696: Downstream signaling of activated FGFR2
R-HSA-5654708: Downstream signaling of activated FGFR3
R-HSA-5654716: Downstream signaling of activated FGFR4
R-HSA-1474244: Extracellular matrix organization
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-190242: FGFR1 ligand binding and activation
R-HSA-1839124: FGFR1 mutant receptor activation
R-HSA-190370: FGFR1b ligand binding and activation
R-HSA-190373: FGFR1c ligand binding and activation
R-HSA-190241: FGFR2 ligand binding and activation
R-HSA-1839126: FGFR2 mutant receptor activation
R-HSA-190377: FGFR2b ligand binding and activation
R-HSA-190375: FGFR2c ligand binding and activation
R-HSA-190239: FGFR3 ligand binding and activation
R-HSA-2033514: FGFR3 mutant receptor activation
R-HSA-190372: FGFR3c ligand binding and activation
R-HSA-190322: FGFR4 ligand binding and activation
R-HSA-5658623: FGFRL1 modulation of FGFR1 signaling
R-HSA-5654693: FRS-mediated FGFR1 signaling
R-HSA-5654700: FRS-mediated FGFR2 signaling
R-HSA-5654706: FRS-mediated FGFR3 signaling
R-HSA-5654712: FRS-mediated FGFR4 signaling
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5654726: Negative regulation of FGFR1 signaling
R-HSA-5654727: Negative regulation of FGFR2 signaling
R-HSA-5654732: Negative regulation of FGFR3 signaling
R-HSA-5654733: Negative regulation of FGFR4 signaling
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-5654689: PI-3K cascade
R-HSA-5654695: PI-3K cascade
R-HSA-5654710: PI-3K cascade
R-HSA-5654720: PI-3K cascade
R-HSA-109704: PI3K Cascade
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-2892247: POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
R-HSA-5654219: Phospholipase C-mediated cascade
R-HSA-5654221: Phospholipase C-mediated cascade; FGFR2
R-HSA-5654227: Phospholipase C-mediated cascade; FGFR3
R-HSA-5654228: Phospholipase C-mediated cascade; FGFR4
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-5654688: SHC-mediated cascade
R-HSA-5654699: SHC-mediated cascade
R-HSA-5654704: SHC-mediated cascade
R-HSA-5654719: SHC-mediated cascade
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654736: Signaling by FGFR1
R-HSA-5655302: Signaling by FGFR1 in disease
R-HSA-5654738: Signaling by FGFR2
R-HSA-8851708: Signaling by FGFR2 IIIa TM
R-HSA-5655253: Signaling by FGFR2 in disease
R-HSA-5654741: Signaling by FGFR3
R-HSA-5655332: Signaling by FGFR3 in disease
R-HSA-8853338: Signaling by FGFR3 point mutants in cancer
R-HSA-5654743: Signaling by FGFR4
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-1839122: Signaling by activated point mutants of FGFR1
R-HSA-1839130: Signaling by activated point mutants of FGFR3
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-3000170: Syndecan interactions
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FGF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FGF2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21159663MelanomaInhibit immunityInduction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Supernatants from TGFβ1-treated A375 cells enhanced MCP-1-dependent migration of monocytes, which, in turn, expressed high levels of TGF,β1, bFGF, and VEGF mRNA.
Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FGF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FGF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2130.635
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0380.963
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3450.603
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.040.958
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0240.988
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0530.98
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0570.916
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4790.667
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.410.734
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2780.797
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9930.475
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2490.213
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FGF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FGF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FGF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FGF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FGF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FGF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FGF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFGF2
Namefibroblast growth factor 2 (basic)
Aliases FGFB; BFGF; FGF-2; HBGF-2; basic fibroblast growth factor bFGF; heparin-binding growth factor 2; prostatropi ......
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FGF2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FGF2.
ID Name Drug Type Targets #Targets
DB00364SucralfateSmall MoleculeEGF, FGA, FGB, FGF2, FGG5
DB00686Pentosan PolysulfateSmall MoleculeFGF1, FGF2, FGF43
DB00877SirolimusSmall MoleculeFGF2, FKBP1A, MTOR3
DB01109HeparinSmall MoleculeF10, FGF1, FGF19, FGF2, FGF4, FGFR1, FGFR2, FGFR4, HGF, PF4, SELP, ......12
DB039351,4-Dideoxy-O2-Sulfo-Glucuronic AcidSmall MoleculeANXA5, FGF22
DB03959N,O6-Disulfo-GlucosamineSmall MoleculeANXA5, FGF1, FGF2, HGF, HS3ST3A15
DB039811,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic AcidSmall MoleculeANXA5, FGF2, HS3ST3A13
DB05434ABT-510Small MoleculeCXCL8, FGF2, HGF, VEGFA4